The new definition for NAFLD includes criteria such as obesity (associated in most cases with a fatty liver), type 2 diabetes mellitus (as >70% of patients with type 2 diabetes mellitus have MAFLD) but also includes lean/normal-weight patients with metabolic disorders (prediabetes, dyslipidemia, high blood pressure, pro-inflammatory status revealed by an elevated C-reactive protein) [5]. This evidence concerns the gene CRP and type 2 diabetes mellitus.